Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 249 participants.

Also called NCT05425719

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose other
Phase
Phase 3
Enrolled
  • 249 participants (enrolled count) (from the registry)
Sponsor
MediBeacon (from the registry)
Registry
  • NCT NCT05425719
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05425719. Non-randomized; no masking; primary purpose other. Start 2022-06-14 (actual); primary completion 2023-02-15 (actual). Results posted on 2024-04-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects
Intervention (Drug)
MB-102
Intervention (Device)
MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Lead sponsor
MediBeacon (class: industry)

Record details

Record id
cardio:ct-nct05425719
Content hash
c26af8ec7fb2469c8281b5e9b6e3a7d097db33001462a350ce0bc1a9c30eea03